Protara Therapeutics (NASDAQ:TARA) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Protara Therapeutics (NASDAQ:TARA) in a report published on Monday morning, Benzinga reports. They currently have a $23.00 target price on the stock. HC Wainwright also issued estimates for Protara Therapeutics’ Q2 2024 earnings at ($1.09) EPS, Q3 2024 earnings at ($1.14) EPS, Q4 2024 earnings at ($1.20) EPS, FY2024 earnings at ($4.40) EPS, FY2026 earnings at ($4.41) EPS, FY2027 earnings at ($3.35) EPS and FY2028 earnings at ($1.49) EPS.

Separately, Oppenheimer lifted their price objective on Protara Therapeutics from $26.00 to $30.00 and gave the company an outperform rating in a research note on Monday, April 22nd.

Protara Therapeutics Price Performance

TARA opened at $2.98 on Monday. The firm has a market capitalization of $34.06 million, a price-to-earnings ratio of -0.80 and a beta of 1.80. The company’s 50 day simple moving average is $3.50 and its two-hundred day simple moving average is $2.57. Protara Therapeutics has a 1-year low of $1.04 and a 1-year high of $5.24.

Protara Therapeutics (NASDAQ:TARA) last posted its quarterly earnings results on Wednesday, March 13th. The company reported ($0.90) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.13. On average, equities analysts anticipate that Protara Therapeutics will post -3.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Protara Therapeutics

A hedge fund recently bought a new stake in Protara Therapeutics stock. Oppenheimer & Co. Inc. bought a new stake in Protara Therapeutics, Inc. (NASDAQ:TARA) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 10,000 shares of the company’s stock, valued at approximately $40,000. Oppenheimer & Co. Inc. owned approximately 0.09% of Protara Therapeutics as of its most recent filing with the Securities and Exchange Commission. 38.13% of the stock is owned by institutional investors and hedge funds.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.